tetano
Editor, Senior Moderator
Eur J Pain
. 2022 Nov 11.
doi: 10.1002/ejp.2055. Online ahead of print.
A systematic review and metanalysis of neuropathic pain associated with coronavirus disease 2019
G Di Stefano[SUP] 1 [/SUP], P Falco[SUP] 1 [/SUP], E Galosi[SUP] 1 [/SUP], G Di Pietro[SUP] 1 [/SUP], C Leone[SUP] 1 [/SUP], A Truini[SUP] 1 [/SUP]
Affiliations
Abstract
Background and objective: Neuropathic pain is an occasionally reported complication of coronavirus disease 2019 (COVID-19) that has received increased attention in scientific literature. In this systematic review and metanalysis, we aimed to provide information on the frequency of neuropathic pain associated with COVID-19.
Databases and data treatment: We systematically reviewed and analysed literature regarding neuropathic pain associated with COVID-19. Literature searches were conducted in PubMed, EMBASE, and Cochrane Library databases. We considered prospective and retrospective studies published up until September 2022 (limitations included English language, full-text publications, and studies including at least 10 patients). A random effects metanalysis was performed and heterogeneity and publication bias were assessed.
Results: We identified 149 studies. We included 17 studies in the systematic review, and six studies reporting the frequency of neuropathic pain in the acute/subacute phase of COVID-19 in the metanalysis. The estimated frequency of neuropathic pain ranged between 0.4 and 25%. Forest plot analysis showed that the random effect overall frequency was 10% (95% confidence interval: 5-15%), with a high level of heterogeneity (Chi[SUP]2[/SUP] = 104; Tau[SUP]2[/SUP] = 0.004; df = 5; I[SUP]2[/SUP] = 95%; test for overall effect: Z = 3.584; P < 0.0005). The overall risk of bias was moderate in all studies selected, particularly due to the poor description of neuropathic pain diagnostic criteria.
Conclusions: The pooled estimated frequency of neuropathic pain associated with COVID-19 should be considered with caution due to the high heterogeneity across studies and the poor description of the neuropathic pain diagnostic criteria applied.
. 2022 Nov 11.
doi: 10.1002/ejp.2055. Online ahead of print.
A systematic review and metanalysis of neuropathic pain associated with coronavirus disease 2019
G Di Stefano[SUP] 1 [/SUP], P Falco[SUP] 1 [/SUP], E Galosi[SUP] 1 [/SUP], G Di Pietro[SUP] 1 [/SUP], C Leone[SUP] 1 [/SUP], A Truini[SUP] 1 [/SUP]
Affiliations
- PMID: 36367322
- DOI: 10.1002/ejp.2055
Abstract
Background and objective: Neuropathic pain is an occasionally reported complication of coronavirus disease 2019 (COVID-19) that has received increased attention in scientific literature. In this systematic review and metanalysis, we aimed to provide information on the frequency of neuropathic pain associated with COVID-19.
Databases and data treatment: We systematically reviewed and analysed literature regarding neuropathic pain associated with COVID-19. Literature searches were conducted in PubMed, EMBASE, and Cochrane Library databases. We considered prospective and retrospective studies published up until September 2022 (limitations included English language, full-text publications, and studies including at least 10 patients). A random effects metanalysis was performed and heterogeneity and publication bias were assessed.
Results: We identified 149 studies. We included 17 studies in the systematic review, and six studies reporting the frequency of neuropathic pain in the acute/subacute phase of COVID-19 in the metanalysis. The estimated frequency of neuropathic pain ranged between 0.4 and 25%. Forest plot analysis showed that the random effect overall frequency was 10% (95% confidence interval: 5-15%), with a high level of heterogeneity (Chi[SUP]2[/SUP] = 104; Tau[SUP]2[/SUP] = 0.004; df = 5; I[SUP]2[/SUP] = 95%; test for overall effect: Z = 3.584; P < 0.0005). The overall risk of bias was moderate in all studies selected, particularly due to the poor description of neuropathic pain diagnostic criteria.
Conclusions: The pooled estimated frequency of neuropathic pain associated with COVID-19 should be considered with caution due to the high heterogeneity across studies and the poor description of the neuropathic pain diagnostic criteria applied.